Capmatinib hydrochloride is a Small Molecule owned by Novartis, and is involved in 41 clinical trials, of which 21 were completed, 18 are ongoing, and 2 are planned.
Capmatinib (INC-280, INCB28060) is a highly selective inhibitor of c-Met receptor tyrosine kinase (RTK). The HGF/c-Met pathway is one of the most frequently dysregulated pathways in human cancers. Abnormal c-MET activity triggers tumor growth and formation of new blood vessels that supply the tumor with nutrients and causes cancer to spread to other organs. The c-Met pathway is activated by abnormal HGF and c-Met expression levels, c-Met activating mutations and gene amplifications.
The revenue for Capmatinib hydrochloride is expected to reach a total of $8.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Capmatinib hydrochloride NPV Report.
Capmatinib hydrochloride Overview
Capmatinib hydrochloride (Tabrecta) is a potential antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Tabrecta is indicated as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
Capmatinib (INC-280, INCB28060) is under development for the treatment of solid tumors including advanced hepatocellular carcinoma, gastric cancer, papillary renal cell carcinoma, metastatic triple negative breast cancer, non-small cell lung cancer, glioblastoma multiforme, and advanced or metastatic BRAF V600 melanoma. The drug candidate is administered orally. INC280 acts by targeting c-Met receptor tyrosine kinase (RTK). It was under development for head and neck cancer squamous cell carcinoma and recurrent glioblastoma multiforme.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Capmatinib hydrochloride
|Highest Development Stage|